RT Journal Article
SR Electronic
T1 Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP e13
OP e13
DO 10.1136/annrheumdis-2018-214757
VO 79
IS 2
A1 Fabrizio Cantini
A1 Maurizio Benucci
YR 2020
UL http://ard.bmj.com/content/79/2/e13.abstract
AB